Literature DB >> 8302284

Inhibition of P-type and N-type calcium channels by dopamine receptor antagonists.

D W Sah1, B P Bean.   

Abstract

P-type Ca2+ channels in cerebellar Purkinje neurons and N-type Ca2+ channels in sympathetic neurons were found to be inhibited by D2 dopamine receptor antagonists with diverse structures, including phenothiazines (chlorpromazine and thioridazine), diphenylbutylpiperidines (fluspirilene and pimozide), butyrophenones (haloperidol and spiperone), and a piperazine (fluphenazine). Dopamine and quinpirole had no effect on P-type Ca2+ channels. In all cases, inhibition was characterized by slow onset and offset. The effects of P-type and N-type channels were very similar. Fluspirilene was the most potent of the drugs, with EC50 values of 6 microM for P-type current and 2 microM for N-type current. Block of P-type channels by fluspirilene was voltage dependent, being enhanced by depolarized holding potentials, and use dependent, being enhanced by higher stimulation frequencies. The effect of fluspirilene on the P-type Ca2+ channel current was not prevented by simultaneous exposure to the peptide toxin omega-agatoxin IVA, indicating that fluspirilene binds to a distinct site on the channel. The results suggest that N-type and P-type Ca2+ channels possess similar binding sites for dopamine receptor antagonists and that block of N-type and P-type channels is relatively weak, compared with that of some T-type and L-type Ca2+ channels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8302284

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Action potential initiation and propagation in layer 5 pyramidal neurons of the rat prefrontal cortex: absence of dopamine modulation.

Authors:  Allan T Gulledge; Greg J Stuart
Journal:  J Neurosci       Date:  2003-12-10       Impact factor: 6.167

2.  Depolarization-induced calcium influx in rat mesenteric small arterioles is mediated exclusively via mibefradil-sensitive calcium channels.

Authors:  Lars J Jensen; Max Salomonsson; Boye L Jensen; Niels-Henrik Holstein-Rathlou
Journal:  Br J Pharmacol       Date:  2004-06-01       Impact factor: 8.739

Review 3.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

4.  High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.

Authors:  P Eller; S Berjukov; S Wanner; I Huber; S Hering; H G Knaus; G Toth; S D Kimball; J Striessnig
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

5.  Differential inhibition of T-type calcium channels by neuroleptics.

Authors:  Celia M Santi; Francisco S Cayabyab; Kathy G Sutton; John E McRory; Janette Mezeyova; Kevin S Hamming; David Parker; Anthony Stea; Terrance P Snutch
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

6.  Effects of dopamine and fluphenazine on field potential amplitude in the salamander olfactory bulb.

Authors:  M R Gurski; K A Hamilton
Journal:  Exp Brain Res       Date:  1996-03       Impact factor: 1.972

Review 7.  Molecular pharmacology of high voltage-activated calcium channels.

Authors:  Clinton J Doering; Gerald W Zamponi
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

8.  Inhibitors of cellular signalling are cytotoxic or block the budded-to-hyphal transition in the pathogenic yeast Candida albicans.

Authors:  Kurt A Toenjes; Benjamin C Stark; Krista M Brooks; Douglas I Johnson
Journal:  J Med Microbiol       Date:  2009-06       Impact factor: 2.472

9.  Blockade by sigma site ligands of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurones.

Authors:  J Church; E J Fletcher
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

10.  Acid-evoked Ca2+ signalling in rat sensory neurones: effects of anoxia and aglycaemia.

Authors:  Michael Henrich; Keith J Buckler
Journal:  Pflugers Arch       Date:  2009-11       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.